(Q35108011)

6 August 2017

1 reference

title

The medical management of pancreatic cancer: a review (English)

1 reference

6 August 2017

The Medical Management of Pancreatic Cancer: A Review (English)

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

24 December 2023

1 reference

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

24 December 2023

author name string

Sarah McKenna

1

1 reference

6 August 2017

Martin Eatock

2

1 reference

6 August 2017

language of work or name

1 reference

1 January 2003

1 reference

full work available at URL

6 August 2017

http://theoncologist.alphamedpress.org/content/8/2/149.full.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12697940

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.8-2-149

24 December 2023

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.8-2-149

24 December 2023

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

https://academic.oup.com/oncolo/article-pdf/8/2/149/41840449/oncolo_8_2_149.pdf

24 December 2023

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

24 December 2023

1 reference

6 August 2017

volume

8

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

149-160

1 reference

The National Cancer Data Base report on pancreatic cancer

6 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Chemotherapy for advanced pancreatic cancer: it may no longer be ignored

24 December 2023

3

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Chemotherapy in advanced pancreatic adenocarcinoma

24 December 2023

4

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Chemotherapy for pancreatic carcinoma

24 December 2023

5

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Changes in 18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?

24 December 2023

7

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer

24 December 2023

8

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study

24 December 2023

9

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

24 December 2023

11

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life.

24 December 2023

12

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Preclinical, pharmacologic, and phase I studies of gemcitabine

24 December 2023

13

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

24 December 2023

14

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

24 December 2023

15

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer

24 December 2023

17

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer

24 December 2023

24

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

24 December 2023

25

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma

24 December 2023

26

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population

24 December 2023

27

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts

24 December 2023

28

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

24 December 2023

29

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

24 December 2023

30

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Pharmacology and clinical status of capecitabine

24 December 2023

31

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Future directions in the development of pemetrexed

24 December 2023

32

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

24 December 2023

33

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

24 December 2023

34

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma

24 December 2023

35

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death

24 December 2023

37

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue

24 December 2023

38

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts

24 December 2023

39

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

24 December 2023

40

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan

24 December 2023

41

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma

24 December 2023

42

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study

24 December 2023

43

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.

24 December 2023

44

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy

24 December 2023

45

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Camptothecin analogues: studies from the Johns Hopkins Oncology Center.

24 December 2023

46

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

24 December 2023

47

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer

24 December 2023

48

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma

24 December 2023

49

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

24 December 2023

51

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma

24 December 2023

52

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer

24 December 2023

53

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma

24 December 2023

54

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

24 December 2023

57

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines

24 December 2023

60

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

24 December 2023

61

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB

24 December 2023

62

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

24 December 2023

63

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Current status of clinical trials of farnesyltransferase inhibitors.

24 December 2023

64

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Matrix metalloproteinase inhibition: a review of anti-tumour activity

24 December 2023

68

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application

24 December 2023

69

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer.

24 December 2023

70

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

A phase II trial of marimastat in advanced pancreatic cancer

24 December 2023

72

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

24 December 2023

73

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Development of matrix metalloproteinase inhibitors in cancer therapy.

24 December 2023

74

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia

24 December 2023

76

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

The epidermal growth factor receptor and its inhibition in cancer therapy

24 December 2023

77

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

24 December 2023

78

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

24 December 2023

82

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice

24 December 2023

83

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

24 December 2023

84

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Tumour vasculature as a target for anticancer therapy.

24 December 2023

87

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Correlation of postoperative survival and angiogenic growth factors in pancreatic carcinoma

24 December 2023

88

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Prognostic significance of angiogenesis in human pancreatic cancer

24 December 2023

89

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival

24 December 2023

90

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth

24 December 2023

91

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-2-149

24 December 2023

Identifiers

1 reference

6 August 2017

1 reference